25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Anterogen.Co.Ltd
Buy, Hold or Sell?

Let's analyze Anterogen together

I guess you are interested in Anterogen.Co.Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Anterogen.Co.Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Anterogen.Co.Ltd

I send you an email if I find something interesting about Anterogen.Co.Ltd.

1. Quick Overview

1.1. Quick analysis of Anterogen (30 sec.)










1.2. What can you expect buying and holding a share of Anterogen? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩11,791.41
Expected worth in 1 year
₩11,530.47
How sure are you?
62.1%

+ What do you gain per year?

Total Gains per Share
₩-260.94
Return On Investment
-1.7%

For what price can you sell your share?

Current Price per Share
₩15,230.00
Expected price per share
₩13,700 - ₩17,830
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Anterogen (5 min.)




Live pricePrice per Share (EOD)
₩15,230.00

2.2. Growth of Anterogen (5 min.)




Is Anterogen growing?

Current yearPrevious yearGrowGrow %
How rich?$80.3m$77.7m$9m10.5%

How much money is Anterogen making?

Current yearPrevious yearGrowGrow %
Making money-$404.9k-$648k$243.1k60.0%
Net Profit Margin-35.6%-59.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Anterogen (5 min.)




2.4. Comparing to competitors in the Pharmaceuticals industry (5 min.)




  Industry Rankings (Pharmaceuticals)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Anterogen?

Welcome investor! Anterogen's management wants to use your money to grow the business. In return you get a share of Anterogen.

First you should know what it really means to hold a share of Anterogen. And how you can make/lose money.

Speculation

The Price per Share of Anterogen is ₩15,230. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Anterogen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Anterogen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩11,791.41. Based on the TTM, the Book Value Change Per Share is ₩-65.24 per quarter. Based on the YOY, the Book Value Change Per Share is ₩72.57 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Anterogen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.040.0%-0.040.0%-0.070.0%-0.090.0%-0.060.0%
Usd Book Value Change Per Share0.000.0%-0.050.0%0.050.0%0.150.0%0.280.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%-0.050.0%0.050.0%0.150.0%0.280.0%
Usd Price Per Share10.19-10.51-11.86-25.71-31.90-
Price to Earnings Ratio-68.34--95.17-335.80-148.88-120.21-
Price-to-Total Gains Ratio2,416.78-598.33--1.36-102.90-55.91-
Price to Book Ratio1.23-1.18-1.48-3.67-5.66-
Price-to-Total Gains Ratio2,416.78-598.33--1.36-102.90-55.91-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.661
Number of shares93
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.050.15
Usd Total Gains Per Share-0.050.15
Gains per Quarter (93 shares)-4.2514.12
Gains per Year (93 shares)-16.9956.50
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-17-2705646
20-34-440113102
30-51-610169158
40-68-780226214
50-85-950282270
60-102-1120339326
70-119-1290395382
80-136-1460452438
90-153-1630508494
100-170-1800565550

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%7.022.00.024.1%7.022.00.024.1%
Book Value Change Per Share2.02.00.050.0%7.05.00.058.3%12.08.00.060.0%18.011.00.062.1%18.011.00.062.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share2.02.00.050.0%7.05.00.058.3%12.08.00.060.0%18.011.00.062.1%18.011.00.062.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Anterogen.Co.Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--6.020-65.236+1184%72.566-92%216.968-97%406.600-99%
Book Value Per Share--11791.41112750.746-8%11416.435+3%10853.868+9%9502.559+24%
Current Ratio--45.24226.362+72%4.480+910%8.981+404%10.389+336%
Debt To Asset Ratio--0.0310.089-66%0.136-77%0.156-80%0.204-85%
Debt To Equity Ratio--0.0320.101-69%0.157-80%0.192-83%0.295-89%
Dividend Per Share----0%-0%-0%-0%
Eps---53.226-59.445+12%-95.139+79%-122.734+131%-90.134+69%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap121133784900.000-17%141591477150.000146140894027.500-3%164825079375.000-14%332831620255.500-57%392848838245.172-64%
Net Profit Margin---0.303-0.356+18%-0.596+97%-0.827+173%-0.606+100%
Operating Margin----0%-0.1890%-0.3630%-0.4080%
Operating Ratio--1.2301.935-36%2.059-40%1.335-8%1.554-21%
Pb Ratio1.292+4%1.2341.183+4%1.483-17%3.671-66%5.663-78%
Pe Ratio-71.535-5%-68.341-95.173+39%335.805-120%148.876-146%120.214-157%
Price Per Share15230.000+4%14550.00015017.500-3%16937.500-14%36726.000-60%45578.276-68%
Price To Free Cash Flow Ratio---315.711-100%-31.4040%23.825-100%166.609-100%
Price To Total Gains Ratio2529.732+4%2416.782598.329+304%-1.358+100%102.895+2249%55.905+4223%
Quick Ratio---13.460-100%7.838-100%7.820-100%8.532-100%
Return On Assets---0.004-0.004-4%-0.007+64%-0.010+128%-0.007+68%
Return On Equity---0.005-0.005+2%-0.008+83%-0.012+168%-0.009+105%
Total Gains Per Share--6.020-65.236+1184%72.566-92%216.968-97%406.600-99%
Usd Book Value--80322629.80086857582.387-8%77768286.712+3%71019776.952+13%60412944.541+33%
Usd Book Value Change Per Share--0.004-0.046+1184%0.051-92%0.152-97%0.285-99%
Usd Book Value Per Share--8.2548.926-8%7.992+3%7.598+9%6.652+24%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.037-0.042+12%-0.067+79%-0.086+131%-0.063+69%
Usd Free Cash Flow----142462.1590%-428170.8520%-1291393.2850%-1029842.0070%
Usd Market Cap84793649.430-17%99114034.005102298625.819-3%115377555.563-14%232982134.179-57%274994186.772-64%
Usd Price Per Share10.661+4%10.18510.512-3%11.856-14%25.708-60%31.905-68%
Usd Profit---362572.700-404937.405+12%-648084.442+79%-780338.782+115%-565084.555+56%
Usd Revenue--1196903.4001165274.999+3%1090784.641+10%1127342.338+6%995891.936+20%
Usd Total Gains Per Share--0.004-0.046+1184%0.051-92%0.152-97%0.285-99%
 EOD+3 -4MRQTTM+17 -10YOY+18 -85Y+19 -810Y+19 -8

3.3 Fundamental Score

Let's check the fundamental score of Anterogen.Co.Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-71.535
Price to Book Ratio (EOD)Between0-11.292
Net Profit Margin (MRQ)Greater than0-0.303
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than145.242
Debt to Asset Ratio (MRQ)Less than10.031
Debt to Equity Ratio (MRQ)Less than10.032
Return on Equity (MRQ)Greater than0.15-0.005
Return on Assets (MRQ)Greater than0.05-0.004
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Anterogen.Co.Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.857
Ma 20Greater thanMa 5015,104.000
Ma 50Greater thanMa 10014,924.200
Ma 100Greater thanMa 20015,057.700
OpenGreater thanClose15,100.000
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Anterogen.Co.Ltd

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material. In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-11-18 17:41:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Anterogen earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Anterogen to the Pharmaceuticals industry mean.
  • A Net Profit Margin of -30.3% means that ₩-0.30 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Anterogen.Co.Ltd:

  • The MRQ is -30.3%. The company is making a huge loss. -2
  • The TTM is -35.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-30.3%TTM-35.6%+5.3%
TTM-35.6%YOY-59.6%+24.0%
TTM-35.6%5Y-82.7%+47.1%
5Y-82.7%10Y-60.6%-22.0%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.3%9.8%-40.1%
TTM-35.6%9.5%-45.1%
YOY-59.6%9.9%-69.5%
5Y-82.7%12.9%-95.6%
10Y-60.6%12.6%-73.2%
4.3.1.2. Return on Assets

Shows how efficient Anterogen is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Anterogen to the Pharmaceuticals industry mean.
  • -0.4% Return on Assets means that Anterogen generated ₩0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Anterogen.Co.Ltd:

  • The MRQ is -0.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.4%TTM-0.4%0.0%
TTM-0.4%YOY-0.7%+0.3%
TTM-0.4%5Y-1.0%+0.6%
5Y-1.0%10Y-0.7%-0.3%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.4%3.6%-4.0%
TTM-0.4%3.5%-3.9%
YOY-0.7%5.3%-6.0%
5Y-1.0%5.9%-6.9%
10Y-0.7%4.9%-5.6%
4.3.1.3. Return on Equity

Shows how efficient Anterogen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Anterogen to the Pharmaceuticals industry mean.
  • -0.5% Return on Equity means Anterogen generated ₩0.00 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Anterogen.Co.Ltd:

  • The MRQ is -0.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -0.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.5%TTM-0.5%+0.0%
TTM-0.5%YOY-0.8%+0.4%
TTM-0.5%5Y-1.2%+0.7%
5Y-1.2%10Y-0.9%-0.3%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.5%4.6%-5.1%
TTM-0.5%4.6%-5.1%
YOY-0.8%8.2%-9.0%
5Y-1.2%9.1%-10.3%
10Y-0.9%10.3%-11.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Anterogen.Co.Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Anterogen is operating .

  • Measures how much profit Anterogen makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Anterogen to the Pharmaceuticals industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Anterogen.Co.Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-18.9%+18.9%
TTM-5Y-36.3%+36.3%
5Y-36.3%10Y-40.8%+4.5%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.2%-13.2%
TTM-12.0%-12.0%
YOY-18.9%12.4%-31.3%
5Y-36.3%8.6%-44.9%
10Y-40.8%12.1%-52.9%
4.3.2.2. Operating Ratio

Measures how efficient Anterogen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operation Ratio of 1.23 means that the operating costs are ₩1.23 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Anterogen.Co.Ltd:

  • The MRQ is 1.230. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.935. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.230TTM1.935-0.705
TTM1.935YOY2.059-0.124
TTM1.9355Y1.335+0.601
5Y1.33510Y1.554-0.219
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2301.225+0.005
TTM1.9351.220+0.715
YOY2.0591.311+0.748
5Y1.3351.249+0.086
10Y1.5541.240+0.314
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Anterogen.Co.Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Anterogen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Current Ratio of 45.24 means the company has ₩45.24 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Anterogen.Co.Ltd:

  • The MRQ is 45.242. The company is very able to pay all its short-term debts. +2
  • The TTM is 26.362. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ45.242TTM26.362+18.880
TTM26.362YOY4.480+21.882
TTM26.3625Y8.981+17.381
5Y8.98110Y10.389-1.407
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ45.2422.213+43.029
TTM26.3622.234+24.128
YOY4.4802.028+2.452
5Y8.9812.199+6.782
10Y10.3891.995+8.394
4.4.3.2. Quick Ratio

Measures if Anterogen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Anterogen to the Pharmaceuticals industry mean.
  • A Quick Ratio of 0.00 means the company can pay off ₩0.00 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Anterogen.Co.Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM13.460-13.460
TTM13.460YOY7.838+5.622
TTM13.4605Y7.820+5.640
5Y7.82010Y8.532-0.712
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.926-0.926
TTM13.4600.973+12.487
YOY7.8381.515+6.323
5Y7.8201.591+6.229
10Y8.5321.399+7.133
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Anterogen.Co.Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Anterogen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Anterogen to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.03 means that Anterogen assets are financed with 3.1% credit (debt) and the remaining percentage (100% - 3.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Anterogen.Co.Ltd:

  • The MRQ is 0.031. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.089. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.031TTM0.089-0.059
TTM0.089YOY0.136-0.047
TTM0.0895Y0.156-0.067
5Y0.15610Y0.204-0.048
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0310.345-0.314
TTM0.0890.339-0.250
YOY0.1360.333-0.197
5Y0.1560.315-0.159
10Y0.2040.339-0.135
4.5.4.2. Debt to Equity Ratio

Measures if Anterogen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Anterogen to the Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 3.2% means that company has ₩0.03 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Anterogen.Co.Ltd:

  • The MRQ is 0.032. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.101. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.032TTM0.101-0.069
TTM0.101YOY0.157-0.056
TTM0.1015Y0.192-0.091
5Y0.19210Y0.295-0.103
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0320.547-0.515
TTM0.1010.547-0.446
YOY0.1570.499-0.342
5Y0.1920.476-0.284
10Y0.2950.548-0.253
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Anterogen generates.

  • Above 15 is considered overpriced but always compare Anterogen to the Pharmaceuticals industry mean.
  • A PE ratio of -68.34 means the investor is paying ₩-68.34 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Anterogen.Co.Ltd:

  • The EOD is -71.535. Based on the earnings, the company is expensive. -2
  • The MRQ is -68.341. Based on the earnings, the company is expensive. -2
  • The TTM is -95.173. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-71.535MRQ-68.341-3.194
MRQ-68.341TTM-95.173+26.832
TTM-95.173YOY335.805-430.978
TTM-95.1735Y148.876-244.049
5Y148.87610Y120.214+28.663
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD-71.53527.863-99.398
MRQ-68.34129.844-98.185
TTM-95.17327.532-122.705
YOY335.80523.102+312.703
5Y148.87627.577+121.299
10Y120.21429.248+90.966
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Anterogen.Co.Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM315.711-315.711
TTM315.711YOY-31.404+347.114
TTM315.7115Y23.825+291.885
5Y23.82510Y166.609-142.783
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.531-29.531
TTM315.71129.447+286.264
YOY-31.40426.360-57.764
5Y23.82531.734-7.909
10Y166.60934.357+132.252
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Anterogen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A PB ratio of 1.23 means the investor is paying ₩1.23 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Anterogen.Co.Ltd:

  • The EOD is 1.292. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.234. Based on the equity, the company is underpriced. +1
  • The TTM is 1.183. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.292MRQ1.234+0.058
MRQ1.234TTM1.183+0.051
TTM1.183YOY1.483-0.300
TTM1.1835Y3.671-2.488
5Y3.67110Y5.663-1.991
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD1.2924.659-3.367
MRQ1.2343.381-2.147
TTM1.1833.209-2.026
YOY1.4832.597-1.114
5Y3.6713.278+0.393
10Y5.6634.179+1.484
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-06-302023-09-302023-12-312024-03-312024-06-30
Operating Income  -2,297,613927,381-1,370,232707,125-663,108-288,246-951,3541,609,533658,179



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets118,387,796
Total Liabilities3,641,182
Total Stockholder Equity114,746,614
 As reported
Total Liabilities 3,641,182
Total Stockholder Equity+ 114,746,614
Total Assets = 118,387,796

Assets

Total Assets118,387,796
Total Current Assets45,875,305
Long-term Assets72,512,491
Total Current Assets
Total Current Assets  (as reported)45,875,305
Total Current Assets  (calculated)0
+/- 45,875,305
Long-term Assets
Long-term Assets  (as reported)72,512,491
Long-term Assets  (calculated)0
+/- 72,512,491

Liabilities & Shareholders' Equity

Total Current Liabilities1,013,989
Long-term Liabilities2,627,193
Total Stockholder Equity114,746,614
Total Current Liabilities
Total Current Liabilities  (as reported)1,013,989
Total Current Liabilities  (calculated)0
+/- 1,013,989
Long-term Liabilities
Long-term Liabilities  (as reported)2,627,193
Long-term Liabilities  (calculated)0
+/- 2,627,193
Total Stockholder Equity
Total Stockholder Equity (as reported)114,746,614
Total Stockholder Equity (calculated)0
+/- 114,746,614
Other
Common Stock Shares Outstanding 9,731
Net Working Capital 44,861,316



6.3. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
> Total Assets 
47,005,073
58,184,378
60,298,401
60,047,407
94,169,458
93,546,619
101,441,141
119,872,541
95,515,734
85,579,393
84,593,765
82,337,875
95,774,853
96,193,534
94,204,109
115,197,122
119,646,790
126,576,015
136,700,768
155,099,834
132,939,084
127,177,840
124,132,713
129,327,421
133,526,255
159,825,192
149,431,677
121,092,265
118,387,796
118,387,796121,092,265149,431,677159,825,192133,526,255129,327,421124,132,713127,177,840132,939,084155,099,834136,700,768126,576,015119,646,790115,197,12294,204,10996,193,53495,774,85382,337,87584,593,76585,579,39395,515,734119,872,541101,441,14193,546,61994,169,45860,047,40760,298,40158,184,37847,005,073
   > Total Current Assets 
27,960,683
37,798,234
37,722,708
34,816,406
53,630,152
51,849,374
59,505,339
79,146,706
59,457,914
53,039,729
54,118,133
50,024,692
53,884,206
59,821,572
54,910,596
66,632,798
67,858,203
68,227,660
65,364,839
63,024,996
61,493,618
62,822,478
62,449,414
62,626,128
56,972,772
56,606,742
56,380,301
46,146,673
45,875,305
45,875,30546,146,67356,380,30156,606,74256,972,77262,626,12862,449,41462,822,47861,493,61863,024,99665,364,83968,227,66067,858,20366,632,79854,910,59659,821,57253,884,20650,024,69254,118,13353,039,72959,457,91479,146,70659,505,33951,849,37453,630,15234,816,40637,722,70837,798,23427,960,683
       Cash And Cash Equivalents 
7,275,042
6,504,319
11,858,473
5,006,845
20,053,778
4,106,028
16,840,811
3,485,671
1,964,571
24,569,957
42,074,329
35,478,526
40,069,487
43,096,457
40,113,032
52,019,129
674
403
6,968,326
524
524
3,052
3,902,717
1,852
1,617
2,138,567
1,388,676
1,308,177
0
01,308,1771,388,6762,138,5671,6171,8523,902,7173,0525245246,968,32640367452,019,12940,113,03243,096,45740,069,48735,478,52642,074,32924,569,9571,964,5713,485,67116,840,8114,106,02820,053,7785,006,84511,858,4736,504,3197,275,042
       Short-term Investments 
18,217,440
28,217,440
12,517,440
25,992,658
24,000,000
34,000,000
34,000,000
67,000,000
54,000,000
23,000,000
0
0
0
0
7,806,054
7,686,544
55,073,139
45,996,375
52,040,855
27,850,676
30,597,245
41,208,540
52,065,374
53,713,114
47,465,425
47,603,383
48,945,025
38,941,822
0
038,941,82248,945,02547,603,38347,465,42553,713,11452,065,37441,208,54030,597,24527,850,67652,040,85545,996,37555,073,1397,686,5447,806,054000023,000,00054,000,00067,000,00034,000,00034,000,00024,000,00025,992,65812,517,44028,217,44018,217,440
       Net Receivables 
1,540,526
2,180,906
2,306,379
2,731,902
2,215,587
2,091,451
2,262,278
2,092,814
1,858,461
1,985,825
2,099,965
1,770,877
2,057,369
2,833,175
1,834,079
4,370,079
3,370,028
3,891,610
4,578,545
5,437,010
4,647,499
4,085,453
3,087,746
3,620,047
3,350,491
2,473,272
2,282,063
2,299,886
0
02,299,8862,282,0632,473,2723,350,4913,620,0473,087,7464,085,4534,647,4995,437,0104,578,5453,891,6103,370,0284,370,0791,834,0792,833,1752,057,3691,770,8772,099,9651,985,8251,858,4612,092,8142,262,2782,091,4512,215,5872,731,9022,306,3792,180,9061,540,526
       Inventory 
477,406
458,145
553,905
607,740
695,726
687,358
830,721
905,368
941,816
680,767
1,367,725
2,146,171
1,510,452
2,225,575
2,209,179
1,565,298
1,400,342
1,302,786
1,278,959
1,710,431
1,594,512
1,440,679
2,008,122
1,736,524
2,108,312
2,115,351
1,910,505
1,475,096
0
01,475,0961,910,5052,115,3512,108,3121,736,5242,008,1221,440,6791,594,5121,710,4311,278,9591,302,7861,400,3421,565,2982,209,1792,225,5751,510,4522,146,1711,367,725680,767941,816905,368830,721687,358695,726607,740553,905458,145477,406
       Other Current Assets 
442,203
428,851
476,320
467,348
675,197
812,420
499,433
591,743
685,399
702,373
606,154
671,041
3,685,781
6,656,150
2,912,879
965,025
1,322,944
1,870,528
1,814,781
527,067
562,094
524,680
0
0
0
1
0
269,182
0
0269,18201000524,680562,094527,0671,814,7811,870,5281,322,944965,0252,912,8796,656,1503,685,781671,041606,154702,373685,399591,743499,433812,420675,197467,348476,320428,851442,203
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
61,683,299
66,701,293
76,553,483
103,218,449
93,051,376
74,945,592
72,512,491
72,512,49174,945,59293,051,376103,218,44976,553,48366,701,29361,683,2990000000000000000000000
       Property Plant Equipment 
7,093,269
7,128,994
7,300,572
7,873,472
8,687,709
9,247,148
10,408,292
10,636,691
10,616,513
11,764,197
13,344,601
14,173,838
16,963,361
16,902,420
19,853,690
21,448,670
22,232,910
22,236,767
22,428,563
23,136,754
23,266,876
23,288,189
23,088,403
22,987,189
22,834,742
22,734,829
22,632,835
22,527,797
0
022,527,79722,632,83522,734,82922,834,74222,987,18923,088,40323,288,18923,266,87623,136,75422,428,56322,236,76722,232,91021,448,67019,853,69016,902,42016,963,36114,173,83813,344,60111,764,19710,616,51310,636,69110,408,2929,247,1488,687,7097,873,4727,300,5727,128,9947,093,269
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,715,673
5,715,673
5,715,673
5,715,673
5,715,673
5,715,673
5,715,673
5,715,673
5,715,673
0
05,715,6735,715,6735,715,6735,715,6735,715,6735,715,6735,715,6735,715,6735,715,6730000000000000000000
       Long Term Investments 
8,742,363
9,584,827
11,321,675
13,064,363
27,619,242
27,329,768
28,241,834
26,569,314
21,561,287
16,587,316
15,980,691
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000015,980,69116,587,31621,561,28726,569,31428,241,83427,329,76827,619,24213,064,36311,321,6759,584,8278,742,363
       Intangible Assets 
349,381
347,435
340,510
328,655
322,874
346,742
357,638
349,791
342,407
4,037,579
880,939
889,252
859,704
908,782
849,050
957,415
773,454
726,609
690,244
628,728
568,471
513,226
525,728
463,420
401,114
370,155
340,934
327,448
0
0327,448340,934370,155401,114463,420525,728513,226568,471628,728690,244726,609773,454957,415849,050908,782859,704889,252880,9394,037,579342,407349,791357,638346,742322,874328,655340,510347,435349,381
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
0
0
00101000000000000000000000000
> Total Liabilities 
1,619,877
11,569,228
11,529,913
11,756,011
45,216,253
46,027,392
45,368,412
52,254,987
31,053,175
27,064,637
16,200,116
14,907,658
22,105,820
23,347,109
13,137,043
26,367,041
17,187,305
17,896,728
19,834,172
19,888,683
18,489,599
17,799,202
17,341,328
18,393,136
16,240,352
22,375,728
19,986,740
6,404,238
3,641,182
3,641,1826,404,23819,986,74022,375,72816,240,35218,393,13617,341,32817,799,20218,489,59919,888,68319,834,17217,896,72817,187,30526,367,04113,137,04323,347,10922,105,82014,907,65816,200,11627,064,63731,053,17552,254,98745,368,41246,027,39245,216,25311,756,01111,529,91311,569,2281,619,877
   > Total Current Liabilities 
654,096
665,749
6,475,935
6,665,829
33,088,912
33,676,380
33,421,999
34,293,880
15,542,744
10,933,200
10,054,950
8,762,493
11,283,840
12,572,289
11,689,789
24,919,786
14,135,607
14,779,554
13,754,829
13,165,098
13,817,547
14,732,601
15,037,067
15,004,513
10,689,548
11,155,319
10,758,759
924,920
1,013,989
1,013,989924,92010,758,75911,155,31910,689,54815,004,51315,037,06714,732,60113,817,54713,165,09813,754,82914,779,55414,135,60724,919,78611,689,78912,572,28911,283,8408,762,49310,054,95010,933,20015,542,74434,293,88033,421,99933,676,38033,088,9126,665,8296,475,935665,749654,096
       Short-term Debt 
0
10,000,000
5,126,785
9,381,162
26,590,949
0
0
0
0
0
0
0
0
0
100,000
100,000
100,000
0
0
10,000
10,000
0
0
0
0
0
0
0
0
0000000010,00010,00000100,000100,000100,00000000000026,590,9499,381,1625,126,78510,000,0000
       Short Long Term Debt 
0
10,000,000
5,126,785
9,381,162
26,590,949
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,711,149
13,151,772
9,070,973
9,398,328
9,740,400
0
0
009,740,4009,398,3289,070,97313,151,77212,711,1490000000000000000026,590,9499,381,1625,126,78510,000,0000
       Accounts payable 
77,480
57,048
535,246
611,118
489,768
0
403,107
787,840
514,180
398,801
595,384
627,071
215,520
1,186,767
134,033
48,370
0
0
440,940
145,395
67,150
828,259
941,057
828,619
390,698
951,660
784,828
530,011
0
0530,011784,828951,660390,698828,619941,057828,25967,150145,395440,9400048,370134,0331,186,767215,520627,071595,384398,801514,180787,840403,1070489,768611,118535,24657,04877,480
       Other Current Liabilities 
554,112
574,945
774,386
860,718
5,973,841
6,573,712
3,483,039
3,432,498
1,307,859
1,450,156
1,087,962
763,818
2,399,221
2,487,625
2,263,555
4,747,068
0
0
1,490,992
1,539,938
1,874,657
1,601,024
1
1
0
0
0
0
0
00000111,601,0241,874,6571,539,9381,490,992004,747,0682,263,5552,487,6252,399,221763,8181,087,9621,450,1561,307,8593,432,4983,483,0396,573,7125,973,841860,718774,386574,945554,112
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,304,261
3,388,623
5,550,804
11,220,408
9,227,980
5,479,318
2,627,193
2,627,1935,479,3189,227,98011,220,4085,550,8043,388,6232,304,2610000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
15,103,681
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000015,103,681000000000
       Other Liabilities 
965,781
903,479
859,335
868,659
885,131
937,262
1,616,782
1,631,476
968,902
1,027,755
1,221,866
1,221,866
1,524,524
1,477,364
1,447,254
1,447,254
0
0
6,079,343
6,723,586
4,672,052
3,066,601
0
0
0
0
0
0
0
00000003,066,6014,672,0526,723,5866,079,343001,447,2541,447,2541,477,3641,524,5241,221,8661,221,8661,027,755968,9021,631,4761,616,782937,262885,131868,659859,335903,479965,781
> Total Stockholder Equity
45,385,195
46,615,150
48,768,488
48,291,397
48,953,205
47,519,227
56,072,729
67,617,554
64,462,559
58,514,756
68,393,649
67,430,217
73,669,033
72,846,425
81,067,067
88,830,081
102,459,486
108,679,288
116,866,596
135,211,150
114,449,485
109,378,638
106,791,385
110,934,285
117,285,903
137,449,464
129,444,937
114,688,027
114,746,614
114,746,614114,688,027129,444,937137,449,464117,285,903110,934,285106,791,385109,378,638114,449,485135,211,150116,866,596108,679,288102,459,48688,830,08181,067,06772,846,42573,669,03367,430,21768,393,64958,514,75664,462,55967,617,55456,072,72947,519,22748,953,20548,291,39748,768,48846,615,15045,385,195
   Common Stock
3,976,816
3,976,816
3,976,816
3,976,816
3,976,816
3,976,816
4,219,876
4,325,139
4,325,139
4,325,139
4,325,138
4,325,138
4,477,983
4,477,984
4,546,767
4,546,767
4,710,923
4,710,923
4,710,923
4,865,187
4,865,187
4,865,687
4,865,687
4,865,687
4,865,687
0
0
0
0
00004,865,6874,865,6874,865,6874,865,6874,865,1874,865,1874,710,9234,710,9234,710,9234,546,7674,546,7674,477,9844,477,9834,325,1384,325,1384,325,1394,325,1394,325,1394,219,8763,976,8163,976,8163,976,8163,976,8163,976,8163,976,816
   Retained Earnings Total Equity00000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
70,759,485
85,705,879
85,705,879
87,940,612
87,940,612
96,842,298
83,365,615
91,708,887
91,708,887
91,708,887
98,818,890
98,819,929
98,863,493
98,674,681
98,674,681
98,674,392
0
0
0
0
000098,674,39298,674,68198,674,68198,863,49398,819,92998,818,89091,708,88791,708,88791,708,88783,365,61596,842,29887,940,61287,940,61285,705,87985,705,87970,759,485000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
1,643,362
2,438,774
4,162,493
3,952,968
4,483,742
3,909,424
3,329,381
1,704,646
-1,889,221
-7,799,143
-8,537,165
-8,537,165
-1,115,547
-2,922,026
-2,839,527
4,762,737
4,965,996
11,589,752
20,967,713
34,655,687
16,035,399
10,435,854
7,420,197
11,513,594
19,466,480
0
0
0
0
000019,466,48011,513,5947,420,19710,435,85416,035,39934,655,68720,967,71311,589,7524,965,9964,762,737-2,839,527-2,922,026-1,115,547-8,537,165-8,537,165-7,799,143-1,889,2211,704,6463,329,3813,909,4244,483,7423,952,9684,162,4932,438,7741,643,362



6.4. Balance Sheets

Currency in KRW. All numbers in thousands.




6.5. Cash Flows

Currency in KRW. All numbers in thousands.




6.6. Income Statements

Currency in KRW. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue6,500,250
Cost of Revenue-3,833,896
Gross Profit2,666,3542,666,354
 
Operating Income (+$)
Gross Profit2,666,354
Operating Expense-11,574,092
Operating Income-5,073,843-8,907,738
 
Operating Expense (+$)
Research Development5,383,562
Selling General Administrative731,254
Selling And Marketing Expenses0
Operating Expense11,574,0926,114,816
 
Net Interest Income (+$)
Interest Income1,978,778
Interest Expense-1,526,036
Other Finance Cost-352,991
Net Interest Income99,752
 
Pretax Income (+$)
Operating Income-5,073,843
Net Interest Income99,752
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-2,840,850-5,073,843
EBIT - interestExpense = -1,526,036
-2,840,850
-1,314,814
Interest Expense1,526,036
Earnings Before Interest and Taxes (EBIT)0-1,314,814
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-2,840,850
Tax Provision-0
Net Income From Continuing Ops-2,840,850-2,840,850
Net Income-2,840,850
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-99,752
 

Technical Analysis of Anterogen
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Anterogen. The general trend of Anterogen is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Anterogen's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Anterogen.Co.Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 16,440 < 17,490 < 17,830.

The bearish price targets are: 14,120 > 13,810 > 13,700.

Tweet this
Anterogen.Co.Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Anterogen.Co.Ltd. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Anterogen.Co.Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Anterogen.Co.Ltd. The current macd is 58.95.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Anterogen price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Anterogen. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Anterogen price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Anterogen.Co.Ltd Daily Moving Average Convergence/Divergence (MACD) ChartAnterogen.Co.Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Anterogen.Co.Ltd. The current adx is 18.63.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Anterogen shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Anterogen.Co.Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Anterogen.Co.Ltd. The current sar is 14,282.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Anterogen.Co.Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Anterogen.Co.Ltd. The current rsi is 51.86. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Anterogen.Co.Ltd Daily Relative Strength Index (RSI) ChartAnterogen.Co.Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Anterogen.Co.Ltd. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Anterogen price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Anterogen.Co.Ltd Daily Stochastic Oscillator ChartAnterogen.Co.Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Anterogen.Co.Ltd. The current cci is 17.12.

Anterogen.Co.Ltd Daily Commodity Channel Index (CCI) ChartAnterogen.Co.Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Anterogen.Co.Ltd. The current cmo is 4.13528365.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Anterogen.Co.Ltd Daily Chande Momentum Oscillator (CMO) ChartAnterogen.Co.Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Anterogen.Co.Ltd. The current willr is -46.88995215.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Anterogen is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Anterogen.Co.Ltd Daily Williams %R ChartAnterogen.Co.Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Anterogen.Co.Ltd.

Anterogen.Co.Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Anterogen.Co.Ltd. The current atr is 598.65.

Anterogen.Co.Ltd Daily Average True Range (ATR) ChartAnterogen.Co.Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Anterogen.Co.Ltd. The current obv is 2,376,443.

Anterogen.Co.Ltd Daily On-Balance Volume (OBV) ChartAnterogen.Co.Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Anterogen.Co.Ltd. The current mfi is 45.32.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Anterogen.Co.Ltd Daily Money Flow Index (MFI) ChartAnterogen.Co.Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Anterogen.Co.Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-07-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-11-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-26STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Anterogen.Co.Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Anterogen.Co.Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.857
Ma 20Greater thanMa 5015,104.000
Ma 50Greater thanMa 10014,924.200
Ma 100Greater thanMa 20015,057.700
OpenGreater thanClose15,100.000
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Anterogen with someone you think should read this too:
  • Are you bullish or bearish on Anterogen? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Anterogen? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Anterogen.Co.Ltd

I send you an email if I find something interesting about Anterogen.Co.Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Anterogen.Co.Ltd.

Receive notifications about Anterogen.Co.Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.